Background:This is a randomized, placebo-controlled, parallel-group, multi-center, double-blind, event driven study of vericiguat (MK-1242) in participants with HFrEF. The primary hypothesis is vericiguat (MK-1242) is superior to placebo in increasing the time to first occurrence of the composite of cardiovascular (CV) death or heart failure (HF) hospitalization in participants with HFrEF.Sponsor: Merck Sharp & Dohme Corp.Trial Registration No:NCT02861534 (clinicaltrials.gov) LinkTrial Status:recruiting completedEnrolling Centers:Worldwide:41 countriesCore Study Team: